Drug Type Cell therapy |
Synonyms CS-1 FPBMC |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), SLAMF7 inhibitors(SLAM family member 7 inhibitors), Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plasma cell myeloma refractory | Phase 2 | US | 01 Aug 2023 | |
Relapse multiple myeloma | Phase 2 | US | 01 Aug 2023 |